5 CAR T Cell Therapies With Autoimmune Readouts in 2025 biospace.com/drug-developme…

Marty Makary MD, MPH Enjoy this streamlined thread? Like, Bookmark, retweet please! 🫡🫡🫡 Dr. DD

Remarkable: Baby is given world's first personalized CRISPR therapy seekingalpha.com/news/4449476?g…

Great overview of the major licensing deals in Chinese biotech that happened since 2022 🇨🇳🇪🇺🇺🇸🔥💸 $XBI

For anyone concerned about quantum computing hacking Bitcoin, please listen to Michael Saylor calmly and rationally explain why you should sleep soundly at night.

Would you like more thesis like this? Please support me with a like and retweet the first post! 🙏🏻 x.com/nataninvesting…

Fifty cancer types in one liquid biopsy test: Exact Sciences enters early-detection market statnews.com/2025/09/11/exa… via STAT

Drug ads: are they helping or just selling? In the U.S., drug companies can advertise directly to us on TV and online. Those ads often spotlight expensive brands and breeze past risks. The FDA can step in if an ad is misleading, but that usually happens after the ad has already

Is it just my imagination, or is the frequency of CRLs increasing? $FBIO $SRRK $CAPR $OTLK $PTCT $RHHBY $REPL $UNCY

Hims & Hers will stop offering its Wegovy 'copycat' drug after regulatory scrutiny. They’ve been down this road before and knew better. In my view, greed clouded judgment and pushed them to mass-market compounded semaglutide in violation of FDA regulations. Glad regulators

Hims & Hers to Stop Offering Wegovy Copycat Drug After Regulatory Scrutiny barrons.com/articles/hims-… via Barron's

Why does it feel like the management teams at $LLY and $NVO are throwing a whole pot of spaghetti at the wall—and then writing a press release about whichever strand sticks? LOL. firstwordpharma.com/story/7049088

2nd time is the charm? All we need now is for RFK Jr. to focus on food instead of pharma and then perhaps the FDA can get back to orderly, predictable business.

Friday (tomorrow) is the PDUFA for RYTM's Imcivree for acquired hypothalamic obesity—in contradistinction to its prior approvals for genetic causes of obesity. While it is already approved for Bardet-Biedl syndrome (BBS), Pro-opiomelanocortin (POMC) deficiency, Proprotein

Wow.

Sarepta Therapeutics $SRPT shares rise on early promise for rare disease drugs. New results from small studies could support the beleaguered company’s pivot. statnews.com/2026/03/25/sar… via Damian Garde

$SYRE SPY001 Results announced this am. Conference call at 8 AM EST this am.

#TVTX Approval for Filspari: Not quite clean, but good enough, given the endpoint issue.

Kailera overtakes Moderna-era IPO with $625M raise $KLRA firstwordpharma.com/story/7183127

The weight loss sector is back in the saddle again.